BSGM Archives - BioTuesdays

Developments

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is an orally...

July 13, 2020

Developments

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), submitted an IND application to the FDA to conduct a Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is a...

April 24, 2020

Executive Moves

BioSig appoints John Osborn as consultant on autonomic neuromodulation

BioSig Technologies (NASDAQ:BSGM) signed a consulting agreement with John Osborn, Prof. in the Department of Surgery and director of the Minnesota Consortium for Autonomic Neuromodulation at University of Minnesota...

March 4, 2020

Executive Moves

BioSig names Samuel Navarro to board

BioSig Technologies (NASDAQ:BSGM) appointed Samuel Navarro as an independent director.

June 25, 2019

Feature

BioSig unlocking future of bioelectronic medicine through signal processing

Kenneth Londoner, Founder, Chairman and CEO By Len Zehr With the FDA’s 510(k) clearance of its PURE EP System in August 2018 and first successful patient cases, BioSig (NASDAQ:BSGM) is advancing its vision to improve...

April 9, 2019

Executive Moves

BioSig appoints Barry Keenan as VP of engineering

BioSig Technologies (NASDAQ:BSGM) named Barry Keenan as VP of engineering to head up the company’s advanced product development.

March 6, 2019

Executive Moves

BioSig appoints John Kowalski as VP of sales

BioSig Technologies (NASDAQ:BSGM) named John Kowalski as VP of sales to lead the commercial launch of the PURE EP signal acquisition and processing system, which is designed to improve the diagnosis and treatment of...

February 5, 2019

Tag - BSGM

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

BioSig appoints John Osborn as consultant on autonomic neuromodulation

BioSig names Samuel Navarro to board

BioSig unlocking future of bioelectronic medicine through signal processing

BioSig appoints Barry Keenan as VP of engineering

BioSig appoints John Kowalski as VP of sales

General

More